Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants : Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year.
METHODS: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it).
RESULTS: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose.
CONCLUSIONS: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 9 vom: 02. Apr., Seite 2370-2379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Merdrignac, Lore [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hospital surveillance |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2024.02.090 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36961786X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36961786X | ||
| 003 | DE-627 | ||
| 005 | 20240425233130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.02.090 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM36961786X | ||
| 035 | |a (NLM)38472070 | ||
| 035 | |a (PII)S0264-410X(24)00272-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Merdrignac, Lore |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants |b Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year | ||
| 520 | |a METHODS: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it) | ||
| 520 | |a RESULTS: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose | ||
| 520 | |a CONCLUSIONS: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hospital surveillance | |
| 650 | 4 | |a Pertussis | |
| 650 | 4 | |a Pertussis vaccine | |
| 650 | 4 | |a Vaccine effectiveness | |
| 650 | 4 | |a Whooping cough | |
| 650 | 7 | |a Pertussis Vaccine |2 NLM | |
| 700 | 1 | |a Aït El Belghiti, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Pandolfi, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta, Lesly |e verfasserin |4 aut | |
| 700 | 1 | |a Fabiánová, Kateřina |e verfasserin |4 aut | |
| 700 | 1 | |a Habington, Adele |e verfasserin |4 aut | |
| 700 | 1 | |a García Cenoz, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Bøås, Håkon |e verfasserin |4 aut | |
| 700 | 1 | |a Toubiana, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Tozzi, Alberto E |e verfasserin |4 aut | |
| 700 | 1 | |a Jordan, Iolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Zavadilová, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, Niam |e verfasserin |4 aut | |
| 700 | 1 | |a Navascués, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Flem, Elmira |e verfasserin |4 aut | |
| 700 | 1 | |a Croci, Ilena |e verfasserin |4 aut | |
| 700 | 1 | |a Jané, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Křížová, Pavla |e verfasserin |4 aut | |
| 700 | 1 | |a Cotter, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandino, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Bekkevold, Terese |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Almagro, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Bacci, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Kramarz, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Kissling, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Savulescu, Camelia |e verfasserin |4 aut | |
| 700 | 0 | |a Renacoq Group |e verfasserin |4 aut | |
| 700 | 0 | |a PERTINENT Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 9 vom: 02. Apr., Seite 2370-2379 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:9 |g day:02 |g month:04 |g pages:2370-2379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2024.02.090 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 9 |b 02 |c 04 |h 2370-2379 | ||